T2 Biosystems Announces Letter of Intent to Enter Strategic Partnership for Lyme Disease
May 07, 2024 09:00 ET
|
T2 Biosystems, Inc.
Filed Pursuant to Rule 433Issuer Free Writing Prospectus dated May 6, 2024Relating to Preliminary Prospectus dated May 6, 2024Registration No. 333-278866 LEXINGTON, Mass., May 07, 2024 (GLOBE...
T2 Biosystems Announces First Quarter 2024 Financial Results
May 06, 2024 16:34 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes,...
T2 Biosystems Announces Commercial Expansion Through Middle East Distributor
May 06, 2024 16:34 ET
|
T2 Biosystems, Inc.
Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated May 6, 2024 Relating to Preliminary Prospectus dated May 6, 2024 Registration No. 333-278866 LEXINGTON, Mass., May 06, 2024 (GLOBE...
T2 Biosystems Announces the Conversion of an Additional $15 Million of CRG Term Loan into Equity
May 06, 2024 16:29 ET
|
T2 Biosystems, Inc.
Filed Pursuant to Rule 433Issuer Free Writing Prospectus dated May 6, 2024Relating to Preliminary Prospectus dated May 6, 2024Registration No. 333-278866 LEXINGTON, Mass., May 06, 2024 (GLOBE...
T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024
April 24, 2024 09:00 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today...
T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity
April 11, 2024 16:05 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced...
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
March 28, 2024 09:00 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced...
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates
March 20, 2024 07:30 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes,...
T2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business Updates
March 19, 2024 09:00 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes,...
T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel
March 18, 2024 09:00 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes,...